Navigation Links
Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
Date:11/7/2012

ircumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact: 

Investor Relations Contact:Richard ZarembaJoe Diaz, Lytham Partners631 694 9555

602 889 9700invest@misonix.com 

mson@lythampartners.comMISONIX, INC. And SubsidiariesConsolidated Statements of OperationsUnauditedThree Months EndedSeptember 30,2012

2011Net sales

$4,570,525

$3,217,199Cost of goods sold

1,843,899

1,453,407Gross profit

2,726,626

1,763,792Selling expenses

1,458,564


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Misonix Announces New Distribution Agreement For Panama
2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
3. Misonix Exhibits at Major Worldwide Spine Conference
4. Misonix Adds Industry Veteran To Management Team
5. Misonix Participates In Cleveland Spine Review
6. Misonix And Soelim Create New Distribution Alliance For South Korea
7. Misonix Inks New Distribution Agreement For Croatia And Slovenia
8. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
9. Misonix Adds 6 Spine Sales Agencies In The U.S.
10. Misonix Product Featured At Neurosurgery Congress
11. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... has announced today that they have received CE ... Device. Velox CD™ provides a safe and predictable ... procedures. The single size velox CD™ is indicated ... 5F to 8F.  Velox CD™ utilizes ...
(Date:7/30/2014)... 2014  InnoPharma, Inc. today announced the first generic ... of Zyprexa® injection), in Canada.  Olanzapine is indicated for ... patients with schizophrenia or bipolar I mania. ... has entered into an agreement with Sandoz Canada Inc., ... use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... WIXOM, Mich., Sept. 19 Rockwell Medical,Technologies, ... innovative manufacturer and,developer of concentrates and specialty ... announced today that it has commenced,enrollment in ... Ferric,Pyrophosphate (SFP), a physiological iron-maintenance therapy drug. ...
... ALEXANDRIA, La., Sept. 18 Life Recovery ... an emerging provider of,groundbreaking medical devices for the ... System has been granted European CE,Mark (Conformite Europeene) ... e.g., to induce hypothermia in patients to,preserve cardiac ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed ... study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel ...
(Date:7/30/2014)... 2014 The Ehlers-Danlos National Foundation (EDNF) ... Sandra Aiken Chack will serve as chair. The board ... 2014 Annual Learning Conference in Houston, Texas July 10-12. ... agenda ahead of us. From the rollout of the ... the Greater Baltimore Medical Center to our September physicians ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help consumers ... Quote tool on its website, LTCconsumer.com , announced Nathan ... free and unlimited. , The Instant Quote tool ... age, gender, and state of residence – and delivers a ... enter any contact information to get started). There is no ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... to U.S. Sens. Thad Cochran (R-MS) and Roger ... improvements in telemedicine coverage under Medicare, Medicaid and ... Wicker, both Mississippi Republicans, introduced the Telehealth Enhancement ... a House version, H.R. 3306, introduced by Rep. ...
(Date:7/30/2014)... 2014 Hospitals continually face the ... care that their practitioners provide. During a recent ... discussed the importance of establishing effective peer review ... and quality of care. , With regard ... Rowe elaborated on setting performance expectations, conducting regular ...
Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... Toronto Stock Exchange Symbol: CYT, MONTREAL, May ... cryotherapy products to treat cardiac,arrhythmias, today announced financial results ... Selected Second Quarter Financial and Operational Highlights:, - ... $10.2 million or a 37.6% ...
... N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... services, announced today that it is scheduled to,present from ... 2008 at the 2008,Citi Investment Research Global Health Care ... available to the public via a live audio web,cast, ...
... IQ more likely the younger a child is at diagnosis, study ... 5 percent of people with multiple sclerosis are diagnosed when they,re ... function, causing memory and attention problems, and possibly low IQ scores. ... of diagnosis, the more likely he or she is to have ...
... even harm cognitive function , , MONDAY, May 12 (HealthDay News) ... daily use of two popular pain-relieving drugs, Celebrex and naproxen, ... history of Alzheimer,s disease. , In fact, naproxen, which goes ... a deleterious effect on cognitive function, the study found. ...
... than 2,000,hospital employees, patients and others concerned about the ... State House today in the "Care,Today, Gone Tomorrow" rally ... Toting signs that read "Some Cuts Never Heal" ... and state lawmakers to restore,the $143 million in charity ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3Health News:Celebrex, Naproxen Won't Prevent Mental Decline 2Health News:Celebrex, Naproxen Won't Prevent Mental Decline 3Health News:Crowd Rallies to Protest Hospital Cuts 2Health News:Crowd Rallies to Protest Hospital Cuts 3Health News:Crowd Rallies to Protest Hospital Cuts 4Health News:Research shows timing improves cleft palate surgery 2
... F340 is a basic laboratory system for ... results can be obtained when used with ... electrode. • Fast and easy one and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... the multifunctional high-end microplate reader with outstanding ... modes., Fluorescence Intensity - FRET , ... HTRF, AlphaScreen , Luminescence , ... emission microplate reader with fastest read times. ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
... for Ultra High Throughput Screening (UHTS), ... detection performance. Allows for smooth transfer ... development by sharing all the detection ... fluorescence intensity, fluorescence polarization, time-resolved fluorescence, ...
Medicine Products: